A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

June 6, 2008

A New Improved HIV Tropism Test

A new version of the Trofile HIV tropism test is far more effective than the original assay at determining whether a person will likely respond to the entry inhibitor Selzentry (maraviroc), according to a press release issued by Monogram Biosciences. The test is now available to anyone who needs tropism testing.

Tropism testing is necessary if Selzentry is to be included in an antiretroviral regimen and is used to determine which coreceptor on CD4 cells a person’s HIV is using: CCR5, CXCR4 or both (dual/mixed). Selzentry is effective against CCR5-using HIV only, not dual/mixed or CXCR4-using virus.

The original Trofile test, which became available with the approval of Selzentry last August, was only sensitive enough to accurately detect dual/mixed virus if it made up more than 10 percent of the HIV population in a person’s blood sample. This meant that a significant number of people were at risk of receiving a test result indicating that Selzentry should work well, only to quickly experience treatment failure. The new enhanced Trofile test is 100 percent sensitive at detecting dual/mixed virus making up as little as 0.3 percent of the HIV population in a blood sample.

A representative for Monogram stated that there will be no increase in price over the older Trofile test.

Search: Trofile, Monogram, Biosciences, tropism, Selzentry, maraviroc


Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 2 (of 2 total)    

Brian Greul, Houston, 2008-06-10 14:17:31
Schering Plough is currently doing Phase III trials for vicriviroc (their entry inhibitor) and they will do the trofile assay as part of the screening. They have trials for both treatment naive and treatment experienced people.

Jauri, SF, 2008-06-09 12:29:27
I was really looking forward to get this test and try Selzentry but unfortunately i cannot afford the $2K price for it , the good news is that the treatments available are really good as well , I'm newly infected and drug naive, but for people with resistance issues this can be a miracle drug , i really hope it works for the best as a new class , we are very lucky to have this advanced new approaches , good luck to all .

comments 1 - 2 (of 2 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dulce_angelita
    Bronx
    New York


    Luvlyfe27
    Huntsville
    Alabama


    MascGeek
    Houston
    Texas


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.